Clifton C. Mo

Oncology
450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Journal: Expert opinion on investigational drugs
Published: April 23, 2026

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

Journal: Expert opinion on biological therapy
Published: March 17, 2026

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Journal: Haematologica
Published: March 13, 2026

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Journal: Expert opinion on emerging drugs
Published: October 30, 2025

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Journal: Biomolecules
Published: May 02, 2025

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Journal: Blood advances
Published: March 17, 2025

SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma.

SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 02, 2025

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: European journal of haematology
Published: October 23, 2024

Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial.

Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial.

Journal: JMIR research protocols
Published: July 31, 2024

Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.

Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.

Journal: Expert review of hematology
Published: July 26, 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Journal: Blood reviews
Published: May 01, 2024

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.

Journal: The Lancet. Haematology
Published: December 21, 2023
Showing 1-12 of 34

Last Updated: 09/26/2026